SequelSEC

ProPhase Labs, Inc. PRPH

Pharmaceutical Preparations · CIK 0000868278 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$1.01M
Fiscal year ended 2026-06-30
Operating income
-$2.64M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

ProPhase Labs, Inc. (PRPH) reported revenue of $1.01M and net income of -$3.05M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from ProPhase Labs, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

ProPhase Labs, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Revenue$1.01M$1.17M$784.00K$883.00K$1.25M$1.43M$1.49M$1.42M$1.50M$2.36M
Cost of revenue$785.00K$874.00K$537.00K$1.01M$513.00K$905.00K$1.64M$1.20M$1.66M$2.42M
Gross profit$226.00K$295.00K$247.00K-$123.00K$734.00K$526.00K-$150.00K$215.00K-$155.00K-$60.00K
Operating income-$2.64M-$2.43M-$5.73M-$4.76M-$3.89M-$3.66M-$17.29M-$6.48M-$7.23M-$7.63M
Net income-$3.05M-$5.18M-$7.40M-$6.84M-$4.47M$3.97M-$34.36M-$6.59M-$6.15M-$6.26M
Research & developmentUnavailableUnavailable$0$6.00K$4.00K$97.00K$60.00K$122.00K$140.00K$272.00K
Weighted-average diluted sharesshares 14.02Mshares 12.32MUnavailableshares 41.54Mshares 4.15Mshares 3.52MUnavailableshares 19.08Mshares 18.89Mshares 17.21M
Pretax income-$3.04M-$3.80M-$8.02M-$7.00M-$3.69M-$4.68M-$19.02M-$7.47M-$7.75M-$8.09M
Income tax expense$12.00K$1.37M-$622.00K-$157.00K$779.00K$0$14.56M-$2.51M-$2.29M-$2.57M
Diluted EPS$-0.22$-0.42Unavailable$-0.16$-1.08$1.13Unavailable$-0.35$-0.33$-0.36
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$2.87M$2.72M$5.97M$4.64M$4.62M$4.09M$17.08M$6.57M$6.93M$7.30M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ProPhase Labs, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$20.00K$31.00K$90.00K$405.00K$169.00K$88.00K$678.00K$501.00K$1.78M$1.18M
Total assets$57.41M$58.47M$59.87M$65.70M$42.04M$50.11M$63.20M$91.81M$93.68M$90.03M
Current assets$2.80M$2.85M$3.15M$7.77M$24.57M$24.77M$30.64M$42.24M$44.14M$45.04M
Total liabilities$60.52M$58.90M$56.36M$58.84M$30.60M$34.99M$55.85M$53.68M$49.60M$45.16M
Current liabilities$58.09M$55.67M$53.08M$55.29M$25.63M$24.05M$32.13M$28.70M$28.01M$23.91M
Total equity incl. NCI-$3.11M-$435.00K$3.51M$6.86M$11.44M$15.12M$7.35M$38.13M$44.08M$44.87M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$70.00K$70.00K$70.00K$266.00K$830.00K$1.14M$1.14M$3.97M$3.87M$3.76M
Accounts receivable$1.54M$1.54M$1.54M$3.28M$20.09M$20.20M$20.06M$31.64M$32.94M$35.12M
Goodwill$3.97M$3.97M$3.97M$3.97M$5.23M$5.23M$5.23M$5.23M$5.23M$5.23M
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailable$15.03M$13.33M$13.72M$15.46M$13.63M$11.76M

Cash flow

ProPhase Labs, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$78.00K-$748.00K-$1.23M-$3.49M-$247.00K-$3.38M-$3.52M-$4.04M-$4.84M-$5.14M
Capital expendituresUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow$0$12.00K$0$0$67.00K$853.00K-$40.00K-$97.00K$124.00K$2.44M
Financing cash flow$67.00K$677.00K$915.00K$3.72M$261.00K$1.94M$3.74M$2.86M$5.32M$2.27M
Net change in cash-$11.00K-$59.00K-$315.00K$236.00K$81.00K-$590.00K$177.00K-$1.28M$605.00K-$434.00K
Stock-based compensation$375.00K$390.00K$433.00K$431.00K$508.00K$521.00K$617.00K$636.00K$796.00K$1.59M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$0$0$0$0
Depreciation & amortization$623.00K$962.00K-$599.00K$698.00K$1.01M$1.48M$1.52M$1.53M$1.53M$1.60M

Derived

ProPhase Labs, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flowUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross margin22.4%25.2%31.5%-13.9%58.9%36.8%-10.0%15.2%-10.3%-2.5%
Operating margin-261.6%-207.5%-730.4%-539.5%-312.3%-256.0%-1157.3%-457.6%-480.6%-323.9%
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenue37.1%33.4%55.2%48.8%40.7%36.4%41.3%44.9%52.9%67.4%
Current ratio0.05x0.05x0.06x0.14x0.96x1.03x0.95x1.47x1.58x1.88x
Revenue YoY growth-18.9%-18.3%-47.5%-37.6%-17.1%-39.3%Unavailable-83.1%-88.6%-87.8%
Net margin-301.8%-442.7%-943.6%-774.5%-358.6%277.1%-2299.8%-465.2%-409.1%-265.9%
R&D / revenueUnavailableUnavailable0.0%0.7%0.3%6.8%4.0%8.6%9.3%11.5%
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PRPH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-19View SEC filing
10-Q/A · Filed 2026-07-09View SEC filing
10-Q/A · Filed 2026-07-07View SEC filing
10-Q · Filed 2026-06-30View SEC filing
10-K · Filed 2026-06-01View SEC filing
10-Q · Filed 2025-11-19View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.